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Abstract 
Transporter systems involved in the permeation of drugs and solutes across biological membranes 
are recognized as key determinants of pharmacokinetics. Typically, the action of membrane 
transporters on drug exposure to tissues in living organisms is inferred from invasive procedures, 
which cannot be applied in humans. In recent years, imaging methods have greatly progressed in 
terms of instruments, synthesis of novel imaging probes as well as tools for data analysis. Imaging 
allows pharmacokinetic parameters in different tissues and organs to be obtained in a non-
invasive or minimally invasive way. The aim of this overview is to summarize the current status in 
the field of molecular imaging of drug transporters. The overview is focused on human studies, 
both for the characterization of transport systems for imaging agents as well as for the 
determination of drug pharmacokinetics, and makes reference to animal studies where necessary. 
We conclude that despite certain methodological limitations, imaging has a great potential to study 
transporters at work in humans and that imaging will become an important tool, not only in drug 
development but also in medicine. Imaging allows the mechanistic aspects of transport proteins 
to be studied, as well as elucidating the influence of genetic background, pathophysiological states 
and drug-drug interactions on the function of transporters involved in the disposition of drugs. 
List of Abbreviations 
ABC, ATP-binding cassette ; AD, Alzheimer’s disease ; ADME, Absorption, Distribution, 
Metabolism and Elimination ; ATP, adenosine triphosphate ; AUC, area under the curve ; BBB, 
blood-brain barrier ; BCRP, breast cancer resistance protein ; BPND, non-displaceable binding 
potential ; CL, total clearance ; CT, computed tomography ; CYP, cytochrome P450 ; DDI, drug-
drug interaction; K1, influx rate constant ; k2, efflux rate constant ; MAG3, mercaptoacetyltriglycine 
; MATE, multidrug and toxin extrusion protein ; MDR, multidrug resistance; MRI, magnetic 
resonance imaging ; MRP, multidrug resistance-associated protein ; OAT, organic anion 
transporter ; OATP, organic anion-transporting polypeptide ; OCT, organic cation transporter ; 
  3
OCTN, organic cation / carnitine transporter ; P-gp, P-glycoprotein ; PBPK, physiologically based 
pharmacokinetic ; PET, positron emission tomography ; PK, pharmacokinetics ; SLC, solute carrier 
; SNP, single nucleotide polymorphism ; SPECT, single photon emission computed tomography ; 
TKI, tyrosine kinase inhibitor ; VT, total volume of distribution. 
Keywords 
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magnetic resonance imaging, single photon emission computed tomography 
  
  4
TABLE OF CONTENTS 
 
1.  Introduction ....................................................................................................................... 5 
2.  Imaging methods for in vivo pharmacokinetics .................................................................. 6 
2.1  In vivo imaging modalities ......................................................................................................6 
2.2  Chemistry of imaging probes ..................................................................................................8 
2.3  Modeling transporter function in vivo .................................................................................. 10 
2.4  Metabolism of imaging probes ............................................................................................. 11 
3  Imaging probes to study transporter function .................................................................. 13 
3.1  Liver transporters ................................................................................................................. 13 
3.2  Kidney transporters .............................................................................................................. 16 
3.3  Brain transporters ................................................................................................................ 17 
3.4  Retina transporters .............................................................................................................. 19 
3.5  Lung transporters ................................................................................................................. 20 
3.6  Placenta transporters ........................................................................................................... 21 
3.7  Imaging transporter function in cancer tissues ..................................................................... 22 
4  Discoveries and perspectives enabled by transporter imaging ......................................... 23 
4.1  Implications of the interplay between transporters and metabolism for imaging ................. 23 
4.2  Imaging disease‐induced changes in transporter expression at the BBB ................................ 24 
4.3  Imaging drug‐drug interactions at the tissue level ................................................................ 26 
4.4  Imaging the impact of transporter gene polymorphisms on transporter function ................. 29 
4.5  Animal to clinical extrapolation ............................................................................................ 31 
4.6  Pharmacokinetic imaging to study the fate of drugs at the site of action .............................. 34 
5  Expert opinion and perspectives ...................................................................................... 36 
 
 
 
 
  5
1. Introduction 
The pharmacologic effect of drugs is directly dependent on the local concentration of the drug at 
its respective target and hence critically depends on the pharmacokinetics (PK) of the drug (Fung 
& Jusko, 2015; Levy, 1966). PK includes determining the absorption, distribution, metabolism and 
excretion (ADME) of a drug or xenobiotic, and describes the concentration-time profile, typically 
determined in the circulation (Fan & de Lannoy, 2014). It is evident that sampling drugs in blood 
plasma does not give direct and accurate information on the concentration of a drug at its target, 
which very often is located in tissues, outside of the circulation. Current clinical pharmacokinetic 
studies do not provide information on the penetration of drugs into tissues or across barriers, e.g. 
the blood-brain barrier (BBB), placenta or tumor barriers, to name a few. 
ADME of drugs and xenobiotics is governed by many factors. Crossing of plasma membranes or 
other biological membranes by drugs and other solutes requires in general proteins, i.e. transport 
systems (Kell, 2015). (Drug) transporters can be divided very generally into systems mediating 
the uptake of substances into cells and systems mediating the efflux of substances from cells 
(Hediger et al., 2013). Uptake of solutes into cells is largely mediated by members of the solute 
carrier (SLC) gene series (Hediger et al., 2013). Export may be mediated by SLC transporters or, 
if against steep concentration gradients, by members of the group of adenosine triphosphate 
(ATP)-binding cassette (ABC) transporters. Once in a cell, many drugs and solutes are 
metabolized. Metabolism will affect both the total and intracellular concentration of transporter 
substrates. The interplay of transport into cells and intracellular metabolism generates a dilemma 
in the elucidation of molecular mechanisms involved in drug metabolism and elimination (Benet, 
2009).  
Current methodology for measuring drug concentrations in tissues requires invasive procedures 
(Chu et al., 2013). In such situations, imaging methods come into play, as they allow molecules in 
the body to be visualized in a non-invasive manner and even more so as they allow detailed 
information to be obtained on time-dependent changes in drug concentrations in organs or tissues.  
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In parallel to the acceptance of transporters as the key protein systems allowing the crossing of 
solutes over biological membranes (Giacomini et al., 2010; Hillgren et al., 2013; Suzuki & 
Sugiyama, 2000; van Montfoort et al., 2003), the role of drug transporters in imaging is increasingly 
being appreciated (Kannan et al., 2009; Kilbourn, 2017; Kusuhara, 2013; Langer, 2016; Mann et 
al., 2016; Marie et al., 2017; Stieger et al., 2012; Testa et al., 2015; Van Beers et al., 2012). Non-
invasive imaging methods have therefore been developed to reveal and quantify drug transporter 
function in clearance and non-clearance organs, as a prerequisite to the local 
pharmacologic/toxicological effect, metabolism and elimination. The aim of this review is to provide 
an overview of the application of imaging methods dedicated to the study of drug transporter 
function in vivo.  
2. Imaging methods for in vivo pharmacokinetics 
2.1 In vivo imaging modalities 
Current research in the field of translational imaging of drug transporters is predominantly based 
on clinically feasible imaging approaches. This includes nuclear imaging such as single photon 
emission computed tomography (SPECT) or positron emission tomography (PET) as well as 
magnetic resonance imaging (MRI). All of these approaches rely on the use of drug transporter 
substrates, which are detected using appropriate imaging modalities. The main advantage of 
these imaging techniques is their non-invasive or minimally-invasive nature. This allows a 
repetitive study of the same living subject, including humans, in identical or comparative conditions 
at different time points, thus harnessing the statistical power of longitudinal studies and reducing 
the number of individuals required (Willmann et al., 2008). This contrasts with the more 
conventional destructive biodistribution approaches, in which animals are sacrificed at predefined 
time points. In this framework, molecular imaging benefits from suitable temporal resolution to 
address the impact of carrier-mediated transport systems on the kinetics of drug disposition in vivo 
(Cunha et al., 2014). 
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Scintigraphy captures emitted radiation from administered gamma-emitting radioisotopes to 
create two-dimensional and poorly quantitative “planar” acquisitions. Tomographic acquisitions 
and computed tomography reconstruction (i.e. SPECT) aim at overcoming this limitation by 
providing 3D images of the distribution of the signal. Usually one, two or three detectors are slowly 
rotated around the body, leading to a considerable loss in time-resolution (Frey et al., 2012). 
SPECT has traditionally been considered as a non-quantitative imaging method, but recent 
advances in medical physics have now made SPECT a quantitative method due to coupling with 
a computed tomography (CT) scan in hybrid SPECT/CT scanners. Quantification with clinical 
SPECT/CT scanners, however, remains of slightly lower performance than with PET, especially 
in small volume regions, due to marginally poorer image spatial resolution (typically ~7-10 mm for 
SPECT versus ~5-8 mm for PET) (Bailey & Willowson, 2013). SPECT benefits from good 
sensitivity for the detection of radioactivity, allowing for the use of imaging agents at tracer doses 
with a limited risk of toxicity. Despite its technical limitations, SPECT represents a relevant and 
cost-effective tool for the study of transporter function in a conventional hospital environment (Fig. 
1) (Willmann et al., 2008).  
PET uses radioactive isotopes emitting positrons (ß+ decay), which collide with electrons in the 
tissue. Subsequent annihilation of these particles releases two photons, which can be detected 
and allow calculation of the point where the positron and the electron collided. Today, numerous 
PET tracers are used in medical practice (Vallabhajosula et al., 2011). PET imaging has also been 
used for decades in drug development (Willmann et al., 2008). The advantages of PET over 
SPECT include higher sensitivity (detection efficiency) and better temporal and spatial resolution. 
PET imaging benefits from straightforward 3D quantifiable recordings. Owing to the high sensitivity 
of PET scanners, radiopharmaceutical agents used for PET imaging can be administered at tracer 
doses, usually in the range of a few micrograms (Fig. 1). PET is a functional imaging technique 
which only gives limited anatomical information. For the delineation of organ substructures on PET 
images, anatomical information is often required. This can be obtained either by performing 
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additional scans on stand-alone MRI or CT scanners and co-registration of the data from the two 
imaging modalities, or by using integrated imaging systems (PET/CT, PET/MRI), which provide 
both functional and anatomical information in a single scanning session (Beyer et al., 2000, 2017). 
Compared with nuclear imaging techniques, MRI is a non-irradiant imaging modality. MRI 
measures the energy released in the form of a radiofrequency of atoms, which realign to a strong 
magnetic field after being forced out of this alignment, and requires atomic nuclei with an odd 
number of protons and/or neutrons. MRI produces pictures of anatomy and of physiological 
processes with high spatial resolution and excellent soft tissue contrast. Several MRI contrast 
agents are now available, including paramagnetic gadolinium compounds (Xiao et al., 2016). 
Compared with nuclear imaging, which can be performed using tracer doses of 
radiopharmaceutical agents, the contrast agents used for MRI must be administered at 
pharmacologic doses in order to be detected. The sensitivity is thus limited (micro- to millimolar) 
and quantification of the absolute concentration of the contrast agent is challenging (Sinharay & 
Pagel, 2016). MRI is nonetheless able to capture the rapid temporal signal changes (contrast 
enhancement) associated with the presence of a contrast agent in tissues. MRI thus offers semi-
quantitative data derived from high temporal and spatial resolution images that are of interest for 
studying transporter function in vivo (Georgiou et al., 2017) (Fig. 1).  
2.2 Chemistry of imaging probes 
To date, transporter imaging probes are usually not molecules designed de novo, but are mostly 
derived from known drug molecules, drug metabolites or from endogenous compounds (e.g. bile 
acids) (Kusuhara, 2013; Mairinger et al., 2011; Testa et al., 2015). The classical positron-emitting 
radionuclides for PET imaging are carbon-11 (11C, half-life: 20.4 min) and fluorine-18 (18F, half-
life: 109.7 min). These radionuclides are produced in a cyclotron, and the synthesis of PET 
radiotracers is typically performed immediately before administration in dedicated lead-shielded 
automated synthesis modules. Today, the number of specialized PET centers is limited, which 
limits the applicability of this technique (Willmann et al., 2008) (Fig. 1).  
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11C is the preferred PET radionuclide as it allows radiolabeling of drugs without structural 
modifications. Due to the versatility of PET radiochemistry, PET imaging benefits from a large 
portfolio of available radiotracers when compared with other clinical imaging modalities (Fig. 1). 
11C-labeling is most commonly performed by 11C-methylation of phenolic hydroxyl, carboxylic acid 
or amino groups (Fig. 2). Recent alternative approaches to 11C-labeling have been developed, 
thus giving the possibility of labeling a wider range of chemical structures with 11C (Li & Conti, 
2010). For drugs which contain fluorine, 18F may be employed for radiolabeling (Wuest, 2007). 
The latter offers the advantage of a longer radioactive half-life than that of 11C, thereby enabling 
the measurement of drug tissue PK over several hours (Brunner et al., 2004). A typical 18F-labeling 
reaction is the nucleophilic substitution reaction with [18F]fluoride of suitable leaving groups (Fig. 
2). PET radiochemistry is usually performed at high molar activity (molar activity = ratio of 
radioactivity to mass, given for instance as GBq/µmol). Therefore, the chemical mass of unlabeled 
drug contained in a typically injected amount of a PET tracer (approximately 400 MBq) is very low 
(< 100 µg). This satisfies the definition of a microdose set forth by regulatory authorities, which 
requires less extensive preclinical toxicology testing for applications in humans than is required 
for standard phase one clinical trials, thereby facilitating first-in-human studies (ICH Expert 
Working Group, 2009). 
For SPECT radiochemistry, typical radionuclides for the radiolabeling of small molecules are 
technetium-99m (99mTc, half-life, 6.1 h) and iodine-123 (123I, half-life: 13.3 h). 99mTc allows for 
clinical grade and kit-based preparation of radiopharmaceutical agents for human use and often 
provides labels with suitable metabolic stability in vivo. Several 99mTc-labeled imaging agents used 
in the clinics have been re-purposed as probes for molecular imaging of drug transporters 
(Kusuhara, 2013).  
The variety of available contrast agents for MRI is very limited. MRI contrast agents predominantly 
contain metals (mostly the transition metal gadolinium) associated by complex chemistry. MRI is 
increasingly considered as a molecular imaging method owing to the availability of contrast agents 
  10
to detect molecular processes at the tissue level (Sinharay & Pagel, 2016). Gadoxetate 
(gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid, Gd-EOB-DTPA, Fig. 2) is a MRI 
contrast agent which induces liver-specific contrast enhancement due to transporter-mediated 
uptake into hepatocytes and biliary secretion of gadoxetate (van Montfoort et al., 1999). This 
contrast agent benefits from a suitable complex stability in vivo without any apparent 
biotransformation, making it suitable to study liver transporter function in vivo. 
2.3 Modeling transporter function in vivo 
Of the available imaging techniques, PET is the preferred modality for kinetic modeling purposes 
as it provides fully quantitative tissue concentrations of radioactivity (Fig. 1). For dynamic contrast-
enhanced MRI, conversion of contrast enhancement in tissue into absolute concentration levels 
of contrast agent is feasible but challenging (Ingrisch & Sourbron, 2013; Sourbron & Buckley, 
2013). When the time course of radiotracer in arterial blood (the so-called arterial input function) 
is also known, compartmental modeling approaches can be employed to derive pharmacokinetic 
parameters describing the tissue distribution of radiotracer. The modeling approaches used for 
analysis of imaging data are conceptually similar to modeling approaches used in the 
pharmaceutical sciences, but they employ different terminology (Innis et al., 2007). The gold 
standard to measure the arterial input function is arterial blood sampling. Pharmacokinetic 
modeling of imaging data can, for instance, provide the exchange rate constants of radiotracer 
between plasma and tissue compartments as outcome parameters (Innis et al., 2007). As ABC 
and SLC transporters are localized at blood-tissue interfaces, these exchange rate constants have 
been identified as the key parameters reflecting transporter activities. For example, the activity of 
efflux transporters at the BBB, such as P-glycoprotein (P-gp, ABCB1) or breast cancer resistance 
protein (BCRP, ABCG2), was shown to mainly affect the transfer rate constant of radiotracer from 
plasma into brain (K1). A reduction in efflux transporter activity at the BBB (e.g. by administration 
of a transporter inhibitor) was shown to increase the K1 value (Muzi et al., 2009; Wagner et al., 
2009). Conceptually, efflux transporters at the BBB should also affect the efflux rate constant from 
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brain to plasma (k2) (Syvänen et al., 2006), which was indeed observed for certain compounds 
(Pottier et al., 2016). Inhibition of an uptake transporter in the sinusoidal membrane of hepatocytes 
will lead to a reduction in the transfer rate constant or in the uptake clearance from blood into liver 
(CLuptake,liver), which may be determined with graphical analysis approaches (integration plot 
analysis) (Takashima et al., 2012). Integration plot analysis has also been used to obtain intrinsic 
efflux clearances of radiotracers from liver into bile (CLint,bile) or from kidney into urine (CLint,urine) to 
measure the activities of efflux transporters located at the canalicular membrane of hepatocytes 
or at the brush border membrane of kidney proximal tubule cells, respectively (Shingaki et al., 
2015; Takashima et al., 2013; Traxl et al., 2017).  
Depending on the organ investigated, modeling approaches can become very complex. For 
instance, the modeling of liver data is complicated by the fact that the liver receives dual blood 
supply, via the hepatic artery (~ 25%) and via the portal vein (~ 75%). Portal blood cannot be 
directly sampled in humans. Therefore, modeling approaches either have to rely on image-derived 
portal blood curves, which may be prone to imaging artefacts due to the small size of the 
investigated structures, or on data acquired in preclinical species (e.g. pigs) in which portal blood 
can be sampled (Ørntoft et al., 2017; Sørensen et al., 2016). Figure 3 shows a kinetic model used 
for quantification of hepatic disposition of the radiolabeled bile acid [11C]cholylsarcosine in humans 
(Ørntoft et al., 2017). Similar kinetic modeling approaches to those used for the analysis of PET 
data have also been applied to SPECT data (Pfeifer et al., 2013; Neyt et al., 2013) and to MRI 
data (Sourbron et al., 2012; Saito et al., 2013).  
2.4 Metabolism of imaging probes 
Like most xenobiotics, imaging probes may often undergo significant in vivo biotransformation. 
Paradoxically, “molecular imaging” techniques are devoid of “molecular resolution”. Nuclear 
imaging techniques (PET, SPECT) can only measure total radioactivity in tissues. Radioactivity 
originating from radiolabeled parent drug cannot be distinguished from radioactivity originating 
from radiolabeled metabolites (Pike, 2009). While metal chelates used as probes to study drug 
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transporters with SPECT and MRI often benefit from good in vivo stability, 11C- and 18F-labeled 
small, drug-like molecules used in PET studies often undergo extensive metabolism (Pike, 2009).  
The study of drug transporters with radiotracers which are extensively metabolized can provide 
misleading results, in that changes in radiotracer metabolism can be erroneously interpreted as 
changes in transporter activity. If circulating radiolabeled metabolites are present in blood, total 
radioactivity counts in blood samples can be corrected for these radiolabeled metabolites using 
ex vivo chromatographic methods. On the other hand, radiolabeled metabolites in tissues cannot 
be corrected for and will inevitably contribute to the imaging signal. During radiotracer 
development, tissue-penetrant radiometabolites can be detected and identified in tissue lysates 
obtained from terminal experiments in rodents (Pike, 2009). However, species differences in 
radiotracer metabolism may lead to the presence of tissue-penetrant radiolabeled metabolites in 
humans where not observed in rodents, or vice versa. The contribution of radiolabeled metabolites 
to the tissue PET signal in humans can only be indirectly inferred, for instance by the observation 
that pharmacokinetic modeling yields results which are inconsistent with the presence of a single 
radioactive species. The best approach to assess the contribution of radiolabeled metabolites to 
the PET signal in humans would be to directly radiolabel the metabolite of interest for PET imaging 
experiments, which is, however, very labor intensive and therefore rarely done. However, 
according to the authors’ own experience, PET tracers based on known drug molecules which are 
mainly excreted in the form of metabolites may undergo a relatively low degree of metabolism 
over the short duration of an imaging experiment (e.g. 60-90 min for [11C]radiotracers), so that 
they may still be useful to study transporter function. One such example is erlotinib, for which 
mass balance studies in humans indicated that only < 2% of total radioactivity excreted into feces 
was composed of unmetabolized parent compound (Ling et al., 2006). PET experiments with 
[11C]erlotinib in mice, on the other hand, indicated that at 25 min after radiotracer injection the 
majority of radioactivity in plasma and different tissues and fluids was in the form of unmetabolized 
[11C]erlotinib (Traxl et al., 2015), suggesting that this radiotracer can be used to study transporter 
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function. One approach to overcome the limitation of radiotracer metabolism may be the 
radiolabeling of drug metabolites and their use as transporter imaging probes with better metabolic 
stability, as exemplified by the P-gp imaging probe [11C]N-desmethyl-loperamide (Lazarova et al., 
2008) or by the BCRP imaging probe [11C]SC-62807 (Takashima et al., 2013). Moreover, the 
problem of radiolabeled metabolites can be overcome by performing data analysis over a short 
and early time window after radiotracer injection in which radiotracer metabolism is negligible. For 
instance, the P-gp probe substrate [11C]verapamil is extensively metabolized in vivo, generating 
radiolabeled metabolites which are also P-gp substrates and which are taken up from periphery 
into the brain (Luurtsema et al., 2005). Some investigators have therefore used data from the first 
few minutes after radiotracer injection only, when [11C]verapamil accounts for more than 80% of 
the plasma radioactivity, to determine K1 as a parameter of P-gp function at the BBB (Ikoma et al., 
2006) (Muzi et al., 2009). Similarly, integration plot analysis to determine the uptake clearance of 
radiotracers from blood into the liver usually relies exclusively on data from the first few minutes 
after radiotracer injection, where the contribution of radiolabeled metabolites can often be 
neglected (Kaneko et al., 2018). For the analysis of apical ABC efflux transporters in the liver or 
kidney, on the other hand, good metabolic stability of the PET tracer is mandatory as metabolism 
may otherwise confound the determination of CLint,bile or CLint,urine values. 
 
3 Imaging probes to study transporter function 
3.1 Liver transporters 
The liver is a key organ involved in the metabolism and excretion of xenobiotics. Consequently, 
the expression of a large variety of transporters has been observed in this organ and the role of 
some of these transporters is well established in pharmacokinetic drug-drug interactions (DDIs) 
and in adverse drug actions in the liver. Organic anion-transporting polypeptides (OATPs) have a 
very broad substrate specificity and are key transporters for drugs entering hepatocytes 
(Hagenbuch & Stieger, 2013). In addition, OATPs are known to mediate the transmembrane 
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transport of a considerable number of imaging agents (Marie et al., 2017). The founding members 
of the SLCO gene superfamily encoding OATPs were shown to transport the MRI contrast agent 
gadoxetate (van Montfoort et al., 1999) (Fig. 2). The SPECT tracer [99mTc]mebrofenin (Fig. 2) is 
likewise taken up into the liver via OATPs and can be used for hepatobiliary imaging (de Graaf et 
al., 2011; Ghibellini et al., 2008). However, transport of most hepatic imaging agents is not 
restricted to OATPs but may also include organic anion transporters (OATs), organic cation 
transporters (OCTs) and ABC transporters (Kilbourn, 2017; Mairinger et al., 2011; Stieger et al., 
2014; Testa et al., 2015).  
The transporters for bile salts in hepatocytes have been identified and characterized at the 
molecular level (Hagenbuch & Stieger, 2013; Stieger, 2011). Bile salt derivatives are excellent 
target molecules for developing imaging agents to study liver transporters of importance in PK. 
For example, cholylsarcosine is a synthetic bile acid which is resistant to deconjugation and 
dehydroxylation (Schmassmann et al., 1990). A 11C-labeled version of this bile acid was 
successfully used to visualize in vivo the kinetics of bile acid secretion in pigs (Frisch et al., 2012; 
Sørensen et al., 2016). In a recent proof-of-concept study, this bile acid was found to be a suitable 
probe to non-invasively assess bile flow in humans with liver disease (Ørntoft et al., 2017). In 
addition, the successful synthesis of 11C-labeled derivatives of taurocholic acid, 
taurochenodeoxycholic acid, taurodeoxycholic acid, tauroursodeoxycholic acid and 
taurolithocholic acid was reported (Schacht et al., 2016). All derivatives display comparable 
biodistribution in pigs, and enterohepatic circulation of the taurocholate derivative could be 
observed. Using a different synthetic strategy, an 18F-labeled chenodeoxycholic derivative was 
developed and demonstrated by PET imaging to be concentrated in the liver of mice in a time-
dependent manner (Jia et al., 2014b). However, as the click chemistry-based 18F-labeling reaction 
led to modification of the carboxyl group, some concerns were raised as to whether this tracer was 
handled by the same hepatic transporters as endogenous bile acids (Frisch & Sørensen, 2014). 
Recently, an 18F-labeled derivative of unconjugated cholic acid (3-[18F]fluorocholic acid, Fig. 2) 
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was shown to be a substrate of Na+-taurocholate co-transporting polypeptide (NTCP, SLC10A1), 
OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3) (De Lombaerde et al., 2017), all of which are 
known to be involved in hepatocellular bile acid and bile salt uptake (Stieger, 2011). Furthermore, 
this bile acid derivative inhibited bile salt export pump (BSEP, ABCB11)-mediated taurocholate 
and MRP2-mediated estradiol-17ß-glucuronide transport. In mice, pretreatment with rifampicin or 
bosentan (Fattinger et al., 2000, 2001; Stieger et al., 2000) was shown to interfere with 
hepatocellular transport of 3-[18F]fluorocholic acid (De Lombaerde et al., 2017).  
In addition to studying the function of bile acid transporters, PET has been used to study ABC 
efflux transporter function in the canalicular membrane of hepatocytes. For instance, the 
radiolabeled metabolite of the COX-2 inhibitor celecoxib [11C]SC-62807 was shown to undergo 
biliary secretion mediated by mBCRP and should thus allow measurement of BCRP function in 
the liver (Takashima et al., 2013). PET imaging with [11C]dehydropravastatin allows assessment 
of the transport activities of OATPs and MRP2 (ABCC2) in the rat and human liver (Kaneko et al., 
2018; Shingaki et al., 2013).  
MRI is one of the methods used to examine patients for presence of focal liver lesions (Pastor et 
al., 2014). MRI contrast agents are typically negatively charged (Xiao et al., 2016) and are 
substrates of transport systems for organic anions (Marie et al., 2017). Gadoxetate was found to 
be transported by human OATPB1 and OATP1B3, but not by OATP2B1 (SLCO2B1) (Leonhardt 
et al., 2010). In addition, gadoxetate is a weak substrate of NTCP, which may further contribute to 
its liver uptake (Leonhardt et al., 2010). Gadoxetate was also shown to be transported by MRP2 
(Jia et al., 2014a), which mediates its biliary secretion in rats (Jia et al., 2014a). In one study, 
gadoxetate was found not to be transported by OATP1A2 (SLCO1A2) (van Montfoort et al., 1999), 
while others identified gadoxetate as a substrate of OATP1A2 and MRP3 but not of the apical 
sodium-dependent bile acid transporter (ABST, SLC10A2) and OCT3 (SLC22A3) (Jia et al., 
2014a). Lagadec and coworkers recently reported a correlation between the hepatic extraction 
fraction of gadoxetate and the expression of rOATP1A1 in a rat model of advanced liver fibrosis 
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(Lagadec et al., 2015). BOPTA (gadolinium benzyl-oxypropionictetraacetate) is another MRI 
contrast agent labeled with gadolinium. In situ perfusion of rat livers suggested that BOPTA uptake 
is mediated by rodent OATP transporters. In vitro experiments revealed that BOPTA was 
transported by rOATP1A1, rOATP1A4, rOATP1B2 and by rMRP2 (Planchamp et al., 2007). 
3.2 Kidney transporters 
Renal clearance is a major pathway of drug elimination, which is the result of three concurrent 
processes occurring in the nephron, including glomerular filtration, tubular secretion and tubular 
reabsorption. Glomerular filtration is a passive process, while tubular secretion and reabsorption 
involve drug transporters located in the basolateral and luminal membranes of the tubular 
epithelium (Yin & Wang, 2016). In humans, the major transporters involved in tubular secretion of 
drugs include OCT2 (SLC22A2), OAT1 (SLC22A6), OAT3 (SLC22A8) and OATP4C1 (SLCO4C1) 
in the basolateral membrane and the multidrug and toxin extrusion (MATE) proteins MATE1 
(SLC47A1) and MATE2-K (SLC47A2), P-gp, MRP2 and MRP4 (ABCC4) in the apical membrane 
(Giacomini et al., 2010). Several other related transporters are present in the proximal tubules and 
may also play a role in the renal elimination of drugs and drug metabolites (Yin & Wang, 2016).  
Radionuclide imaging of the kidneys aims at detecting the pathophysiology of the diseased 
kidneys and at achieving an early and sensitive diagnosis (Szabo et al., 2011). Hippurate is a toxic 
urate uremic toxin that accumulates during chronic renal failure. In the past, the renal secretion of 
the exogenous aryl amine derivatives para-aminohippurate and the radiolabeled O-
[131I]iodohippurate were used as markers of tubular function in patients (Lowenstein & Grantham, 
2016). OAT1 was shown to be the main transporter for para-aminohippurate at the proximal tubule 
(Vallon et al., 2008). Radiolabeled derivatives of hippurate such as p-[18F]fluorohippurate have 
been proposed as PET radioligands with improved imaging performance (Awasthi et al., 2011). 
Today, [99mTc]MAG3 (mercaptoacetyltriglycine) clearance from kidneys is used in clinics to 
investigate tubular function in patients (Taylor, 2014). [99mTc]MAG3 is highly protein-bound and 
was shown to be cleared from plasma primarily by OAT1 in the kidneys (Shikano et al., 2004). 
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Furosemide, probenecid and ibuprofen were shown to be competitive inhibitors of renal OAT1 
which impact [99mTc]MAG3 renography (Szabo et al., 2011). Renal secretion of the P-gp substrate 
[99mTc]sestamibi was shown to be inhibited by PSC833, a cyclosporine A derivative developed as 
a P-gp inhibitor (Luker et al., 1997). 
Several PET radiotracers have been developed to investigate other specific transport systems in 
the kidneys. In the kidney, metformin is transported into the proximal tubule via OCT2 and 
excreted into the urine via MATE1 and MATE2-K (Hume et al., 2013). Pedersen et al. performed 
[11C]metformin PET imaging in a mouse model of chronic kidney disease and suggested a 
contribution of mOCT2 in controlling the influx rate constant of [11C]metformin into the renal cortex 
(Pedersen et al., 2016). In pigs, renal clearance of [11C]metformin was approximately 3 times the 
glomerular filtration rate, demonstrating tubular secretion (Jakobsen et al., 2016). Takano and co-
workers showed that sulpriride is a substrate of OCT1 (SLC22A1), OCT2, MATE1, and MATE2-K 
and proposed [11C]sulpiride as a PET probe to study renal OCT function in humans (Takano et 
al., 2017).  
3.3 Brain transporters 
ABC and SLC transporters are expressed in the luminal and abluminal membranes of brain 
capillary endothelial cells forming the BBB, where they control access of exogenous and 
endogenous molecules from blood into brain parenchyma (Abbott et al., 2010; Stieger & Gao, 
2015). Among different ABC and SLC transporters expressed at the BBB, P-gp is the most widely 
studied transporter. Previous review articles have given detailed overviews of radiotracers for 
imaging of P-gp at the BBB (Luurtsema et al., 2016; Mairinger et al., 2011; Raaphorst et al., 2015; 
Wanek et al., 2013). The applicability of the SPECT radioligand [99mTc]sestamibi for imaging P-gp 
function at the BBB is limited due to its very low BBB permeability, even in the absence of P-gp 
function (Cattelotte et al., 2009). Racemic [11C]verapamil, (R)-[11C]verapamil (Fig. 2) and [11C]N-
desmethyl-loperamide are PET tracers which are transported by P-gp and not by BCRP (Kannan 
et al., 2010; Luurtsema et al., 2003; Römermann et al., 2013) and which have been used to 
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visualize P-gp function at the rodent and human BBB in various settings. These radiotracers were 
very useful in measuring the effects of P-gp inhibition at the BBB with inhibitors such as 
cyclosporine A and tariquidar (Bauer et al., 2012; Damont et al., 2016; Kreisl et al., 2015; 
Sasongko et al., 2005). Figure 4 shows PET data on the effect of the third-generation P-gp inhibitor 
tariquidar on brain distribution of (R)-[11C]verapamil in rats and in humans.  
Beside the imaging of P-gp, efforts have also been directed towards the development of PET 
tracers for other ABC transporters at the BBB. Quantitative targeted absolute proteomics work 
indicated that BCRP is the most abundant ABC transporter at the human BBB (Uchida et al., 
2011). The development of BCRP-selective PET tracers is hindered by the overlapping substrate 
specificities between BCRP and P-gp. The few BCRP-selective compounds tested as PET tracers 
to date all possessed similar brain kinetics in wild-type and BCRP knockout mice or rats, 
suggesting lack of suitability to measure BCRP function at the BBB (Hosten et al., 2013; Mairinger 
et al., 2010; Sivapackiam et al., 2016; Takashima et al., 2013). Wanek and co-workers developed 
a PET protocol for visualization of BCRP function at the BBB based on PET scans with the dual 
P-gp/BCRP substrate [11C]tariquidar, in which unlabeled tariquidar is co-administered to inhibit P-
gp at the BBB (Wanek et al., 2012). Okamura et al. developed 6-bromo-7-[11C]methylpurine as a 
PET tracer to measure the function of multidrug resistance-associated protein (MRP1, ABCC1) in 
the brain. The PET tracer crosses the BBB, presumably by passive diffusion, and is converted 
inside the brain by glutathione-S-transferases into its glutathione conjugate, which leaves the brain 
by MRP1 efflux (Okamura et al., 2009). While this radiotracer showed great differences in brain 
clearance between wild-type and Abcc1(-/-) mice, the exact site in the brain at which MRP1 
contributes to radioactivity elimination (e.g. choroid plexus, glia cells or brain capillary endothelial 
cells) has not yet been fully established. Galante and colleagues recently synthesized a 18F-
labeled version of this MRP1 tracer (Galante et al., 2014) for which brain clearance was also 
shown to be dependent on mMRP1 function.  
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In addition to efflux transporters, uptake transporters are also expressed at the BBB. Several 
studies have provided evidence of a novel and molecularly unknown drug/proton (H+)-antiporter 
that controls the permeation of many CNS-targeted drugs across the BBB (e.g. cocaine, clonidine, 
nicotine, oxycodone and diphenhydramine). Two studies have attempted to measure the function 
of this novel transporter by PET imaging. Auvity et al. used the radiolabeled histamine H1-receptor 
antagonist [11C]diphenhydramine to image this transporter at the rat BBB (Auvity et al., 2017). An 
evaluation of radiotracers for the H+-antiporter is complicated by a lack of suitable inhibitors for in 
vivo use. Auvity et al. therefore demonstrated with in situ brain perfusion that uptake transport of 
[14C]diphenhydramine into rat brain can be inhibited by a large excess of unlabeled 
diphenhydramine (10 mM). In addition, they demonstrated poor brain penetration of radiolabeled 
metabolites, allowing for accurate quantification of CLuptake from blood into brain from early PET 
data. Gustafsson et al. performed combined PET imaging and microdialysis in rats with 
[11C]oxycodone, which is also a substrate of the H+-antiporter (Gustafsson et al., 2017). However, 
the utility of this radiotracer for transporter imaging is most likely limited due to extensive 
metabolism and brain uptake of radiolabeled metabolites. To our knowledge, no attempts have so 
far been made to image OATP1A2 and OATP2B1 at the BBB, the latter being considered as target 
transporters for facilitating brain entry of therapeutic drugs (Stieger & Gao, 2015). A potential 
complication in the development of PET tracers for these uptake transporters may be the fact that 
known transporter substrates are also recognized by efflux transporters at the BBB, which may 
mask the effect of the uptake transporters (Taskar et al., 2017; Tournier et al., 2013).  
3.4 Retina transporters 
Drug distribution to the retina after systemic administration is controlled by the blood-ocular 
barriers, i.e. the blood-aqueous humor barrier and the blood-retinal barrier (BRB) (Hosoya et al., 
2011). The BRB is composed of retinal capillary endothelial cells (inner BRB) and retinal pigmental 
epithelial cells (outer BRB) (Mannermaa et al., 2006). Similar to brain capillary endothelial cells, 
these cells are linked by tight junctions, which may limit paracellular diffusion of drugs. The cells 
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comprising the BRB express SLC and ABC transporters, which may control the delivery of drugs 
from blood to the retina (Hosoya et al., 2011; Mannermaa et al., 2006; Stieger & Gao, 2015). P-
gp was shown to be localized at both the luminal membrane of retinal capillary endothelial cells 
and at the apical and basolateral membranes of retinal pigmental epithelial cells (Hosoya et al., 
2011; Mannermaa et al., 2006).  
Invasive experiments in rodents have revealed the functional impact of P-gp at this specific barrier 
(Chapy et al., 2016). Compared with the BBB, mBCRP-mediated efflux was shown to be less 
involved at the BRB, whereas mMRPs were involved to a similar degree at both barriers (Chapy 
et al., 2016). Using (R)-[11C]verapamil PET imaging in healthy volunteers, Bauer et al. reported a 
significant increase in radiotracer distribution to the retina during P-gp inhibition, which provided 
first in vivo evidence for P-gp transport activity at the human BRB. Interestingly, the increase in 
retinal distribution was quantitatively less pronounced than for the brain (Bauer et al., 2017a), 
which correlated well with preclinical data obtained in rodents (Chapy et al., 2016). 
3.5 Lung transporters 
Oral inhalation of therapeutic aerosols is used as a modality for local treatment of respiratory 
diseases (i.e. asthma and chronic obstructive pulmonary disease), but also as a route for systemic 
delivery of small molecule drugs and biologicals. The pharmacokinetic behavior of inhaled drugs 
is much more complicated than that of traditional routes of administration, with several sources of 
variability. There is accumulating evidence that membrane transporters belonging to the SLC and 
ABC families (e.g. organic cation / carnitine transporter 1 and 2 (OCTN1/2, SLC22A4/5), OCT1-
3, MRP1, P-gp and BCRP) are expressed in bronchial, bronchiolar and alveolar epithelial cells 
forming the air-blood barrier (Nickel et al., 2016; Sakamoto et al., 2013). Drug transporters may 
be a source of variability in pulmonary PK of inhaled drugs and thus contribute to heterogeneity in 
treatment response and occurrence of systemic side effects (Nickel et al., 2016). PET and SPECT 
can be used to assess pulmonary disposition of inhaled radiopharmaceuticals (Dolovich & Labiris, 
2004) and may thus also be of use to study the function of pulmonary transporters when 
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radiolabeled transporter substrates are employed. So far, only very few studies have used SPECT 
or PET imaging to investigate pulmonary transporters. Okamura and colleagues reported that 
pulmonary elimination of radioactivity following intravenous injection of 6-bromo-7-
[11C]methylpurine is markedly reduced in Abcc1(-/-) mice as compared with wild-type mice, 
suggesting that this radiotracer can be used to measure pulmonary mMRP1 function (Okamura et 
al., 2013). Two other studies used SPECT imaging to assess pulmonary disposition of inhaled 
[99mTc]sestamibi, a substrate of P-gp and MRP1, in humans (Perek et al., 2000; Piwnica-Worms 
et al., 1993). Ruparelia et al. reported delayed pulmonary elimination of inhaled [99mTc]sestamibi 
in smokers versus non-smokers and hypothesized that this was due to a smoke-induced up-
regulation of pulmonary P-gp (Ruparelia et al., 2008). Mohan et al. confirmed delayed 
[99mTc]sestamibi elimination from the lungs of smokers versus non-smokers and more importantly 
found a correlation between [99mTc]sestamibi elimination and a semi-quantitative measure of 
MRP1 expression in surgically resected lung tissue (Mohan et al., 2016).  
3.6 Placenta transporters 
High expression levels of several ABC and SLC transporters have been reported in the placenta. 
These transporters may play a role in controlling the distribution of drugs across the placental 
barrier (Nishimura & Naito, 2005, 2008). The use of nuclear imaging during pregnancy is restricted 
due to the lack of knowledge regarding the impact of ionizing radiation exposure on the developing 
fetus. However, PET imaging has been proposed to investigate drug exposure to the fetus in 
gestating non-human primates (Benveniste et al., 2003). Eyal and coworkers used [11C]verapamil 
PET imaging in gestating macaques to study the role of P-gp at the placental barrier (Eyal et al., 
2009a). Inhibition of P-gp using cyclosporine A dose-dependently increased [11C]verapamil uptake 
by the fetal brain and liver (Ke et al., 2013). These studies convincingly demonstrated the role of 
P-gp in limiting the placental permeation of its substrates in vivo.  
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3.7 Imaging transporter function in cancer tissues 
Imaging techniques have provided convincing evidence for transporter-mediated multidrug 
resistance (MDR) in cancer tissues. The widespread availability of [99mTc]sestamibi as a SPECT 
tracer in clinical routine allowed for its straightforward application in cancer patients to measure 
P-gp overexpression in tumors in vivo and predict MDR (Derebek et al., 1996). In patients, P-gp 
inhibition resulted in a significant increase in the uptake (Agrawal et al., 2003; Chen et al., 1997) 
and, more importantly, a decrease in the wash-out rate of [99mTc]sestamibi in tumors (Taki et al., 
1998), thus highlighting the functional impact of this transporter on the distribution of its substrates 
to cancer tissues. [99mTc]tetrofosmin, another cationic cardiac imaging agent, has been evaluated 
as an alternative P-gp substrate to predict MDR in cancer (Kao et al., 2001). [99mTc]sestamibi and 
[99mTc]tetrofosmin are not transported by BCRP (Tournier et al., 2009) but are both substrates of 
MRP1, which limits their utility as P-gp specific imaging agents in cancer (Perek et al., 2000). P-
gp substrates radiolabeled with positron emitting isotopes have been further proposed to study 
MDR using PET (Mann et al., 2015). [11C]Verapamil PET imaging has been performed in cancer 
patients, but failed to provide clinical utility (Eary et al., 2011; Hendrikse & Vaalburg, 2002). 
Radiolabeled analogs or derivatives of taxanes such as [11C]docetaxel and [18F]fluoropaclitaxel 
have been evaluated in cancer patients as predictors of successful therapy (Kurdziel et al., 2011; 
van der Veldt et al., 2013a, 2013b).  
Dysregulation of SLC transporters appears to be a common feature in many tumors (El-Gebali et 
al., 2013). In hepatocellular carcinoma, the expression of OATP1B3 decreases in parallel with 
tumor differentiation (Kitao et al., 2011; Miura et al., 2015; Yoneda et al., 2013). This decreased 
expression was found to be paralleled by a reduced gadoxetate-induced signal enhancement in 
the tumor (Tsuboyama et al., 2010). A correlation has been found between the expression of 
OATP1B1 and/or OATP1B3 in pathologic liver cells and signal enhancement (Tsuboyama et al., 
2010). Focal nodular hyperplasia and hepatocellular adenoma are usually difficult to distinguish 
in the absence of contrast enhancement. This distinction is, however, highly important clinically 
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(Pastor et al., 2014). Again, a correlation between OATP1B3 expression and intensity of the 
enhancement was found (Doi et al., 2011; Yoneda et al., 2016). The same tumors may, however, 
also express an efflux system for the contrast agent, e.g. MRP2 or MRP3 (Kitao et al., 2010; Thian 
et al., 2013; Tsuboyama et al., 2010; Vilgrain et al., 2016). These examples highlight the limitations 
of determining in vivo transporter expression/function using imaging agents which are not specific 
to an individual transporter. An alternative approach to distinguish between these two lesions may 
be PET imaging with [18F]fluorocholine. Three patients with hepatocellular adenoma were found 
to show reduced [18F]fluorocholine uptake into the lesion, which correlated with a reduced 
expression of OCT1 and OCT3 (Visentin et al., 2017).  
4 Discoveries and perspectives enabled by transporter imaging 
4.1 Implications of the interplay between transporters and metabolism for imaging 
As the liver is a central organ in drug metabolism and elimination, defining the transport systems 
involved in these processes as well as understanding the role of these transporters in the PK of 
drugs is a very active field of research (Burt et al., 2015; Hillyar et al., 2015; Testa et al., 2015). 
The interplay between transport and metabolism is termed metabolic channeling (Srere & Ovadi, 
1990). The channeling of drugs via transporters into metabolism has been known of at the 
phenomenological level in clinics for quite some time and demonstrated by means of 
pharmacokinetic DDI studies (Benet, 2009; Custodio et al., 2008). One study tested the interaction 
of rifampicin with glyburide disposition in two settings: a single dose of rifampicin led to an increase 
of systemic glyburide exposure, while multiple dosing of rifampicin led to a considerable reduction 
of glyburide exposure (Zheng et al., 2009). Tournier et al. mimicked this glyburide-rifampicin 
interaction using [11C]glyburide PET imaging in non-human primates. Single dose rifampicin 
resulted in a 14-fold decrease in [11C]glyburide uptake by the liver. Reduced liver uptake was 
associated with a pronounced 5-fold increase in [11C]glyburide exposure in plasma. Interestingly, 
radiolabeled metabolites, which accounted for ~30% of total radioactivity in plasma, could not be 
detected in plasma after OATP inhibition (Tournier et al., 2013) (Fig. 5). Imaging may thus be 
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useful to investigate the interplay between transporter-mediated liver uptake and metabolic 
enzymes in controlling the liver metabolism of drugs. Metabolic channeling is gaining attention in 
the drug development and pharmacokinetic community (Varma et al., 2015; Varma & El-Kattan, 
2016). An additional level of complexity is added by the fact that drug metabolites may also interact 
with (efflux) transporters, as exemplified for bosentan (Fattinger et al., 2001) and troglitazone 
(Funk et al., 2001). The issues of metabolic flux and transporter-metabolism interplay have, to our 
knowledge, not been specifically addressed at the mechanistic level with imaging probes in 
different organs. 
4.2 Imaging disease-induced changes in transporter expression at the BBB 
Several PET studies have been conducted using racemic [11C]verapamil or (R)-[11C]verapamil to 
investigate cerebral P-gp function in different patient groups. However, due to the low sensitivity 
of [11C]verapamil to measure moderate changes in P-gp expression/function at the BBB (Wanek 
et al., 2015), most studies found only small differences between patients and control groups. A 
pilot PET study with (R)-[11C]verapamil in seven patients with unilateral temporal lobe epilepsy 
failed to reveal significant differences in (R)-[11C]verapamil distribution between epileptic brain 
tissue and contralateral healthy brain tissue (Langer et al., 2007). Van Assema et al. found no 
differences in (R)-[11C]verapamil volume of distribution (VT) and K1 values, which were shown in 
previous studies to be the key parameters associated with P-gp function at the BBB (Muzi et al., 
2009; Wagner et al., 2009) between Alzheimer’s disease (AD) patients and age-matched control 
subjects (van Assema et al., 2012a). On the other hand, the authors found a significantly higher 
non-displaceable binding potential (BPND) of (R)-[11C]verapamil in AD patients, which they 
hypothesized to reflect a decrease in cerebral P-gp function (van Assema et al., 2012a). In a study 
by Deo et al., differences in brain distribution of [11C]verapamil between AD patients and control 
subjects could only be detected when regional [11C]verapamil K1 values were normalized to 
regional cerebral blood flow, which was lower in AD patients than in control subjects (Deo et al., 
2014). These data suggest that brain distribution of [11C]verapamil depends on cerebral blood 
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flow, as shown before for [11C]N-desmethyl-loperamide (Kreisl et al., 2010; Liow et al., 2009). A 
series of studies used statistical parametrical mapping (SPM) analysis to investigate regional 
differences in brain distribution of racemic [11C]verapamil in Parkinson’s disease and depression 
and schizophrenia patients (Bartels et al., 2008; de Klerk et al., 2009, 2010; Kortekaas et al., 
2005). These studies found small regional differences in [11C]verapamil brain distribution, which 
were attributed to regional differences in P-gp function. There is evidence that P-gp expression at 
the BBB not only changes in the course of different neurological diseases, but also during healthy 
ageing. This could be of therapeutic relevance, as elderly people often take many different drugs 
which could show altered brain distribution if their brain distribution were limited by P-gp. A few 
studies used racemic [11C]verapamil or (R)-[11C]verapamil to compare cerebral P-gp function 
between elderly and young volunteers (Bartels et al., 2009; Bauer et al., 2009; Toornvliet et al., 
2006; van Assema et al., 2012b). These studies consistently found small increases in radiotracer 
brain distribution, both on a global and regional level, in elderly versus young subjects, which 
pointed to an age-related, moderate decline in P-gp function at the BBB. A few studies employed 
a partial P-gp inhibition protocol, which showed improved sensitivity to measure moderate 
changes in P-gp expression/function at the BBB than baseline PET scans (Bankstahl et al., 2011). 
Feldmann et al. demonstrated that patients with pharmacoresistant unilateral temporal lobe 
epilepsy had a lower increase in (R)-[11C]verapamil uptake in the ipsilateral hippocampus in 
response to tariquidar administration than healthy control subjects (24.5% vs. 65% increase in 
(R)-[11C]verapamil K1) (Feldmann et al., 2013). This attenuated response to tariquidar was 
consistent with increased P-gp expression in the hippocampus of pharmacoresistant epilepsy 
patients. Another study used cyclosporine A for partial P-gp inhibition at the BBB and found a 
significantly higher asymmetry in (R)-[11C]verapamil brain concentrations between ipsilateral and 
contralateral temporal lobe brain regions of drug-resistant temporal lobe epilepsy patients as 
compared with drug-sensitive epilepsy patients and healthy control subjects (Shin et al., 2016). 
Bauer et al. demonstrated that the partial P-gp inhibition protocol can also be used to visualize a 
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reduction of P-gp at the BBB as occurs during healthy ageing (Bauer et al., 2017c). They found a 
significantly higher increase in (R)-[11C]verapamil whole-brain VT in elderly versus young subjects 
(+40% vs. + 2%) in response to tariquidar administration. However, the partial P-gp inhibition 
protocol is difficult to use in patients due to safety concerns associated with P-gp inhibition and 
the concomitant use of medication. Clearly, to measure P-gp function at the BBB there is still a 
need for more sensitive PET tracers which do not require administration of a P-gp inhibitor and 
which lack brain-penetrant radiolabeled metabolites.  
4.3 Imaging drug-drug interactions at the tissue level 
Beside drug metabolizing enzymes, transporters may also be implicated in DDIs. In transporter-
mediated DDIs, concomitant administration of two drugs which interact with the same transporters 
may lead to changes in the PK of the drugs as compared to when these drugs are dosed alone, 
due to mutual inhibition or saturation of ABC and SLC transporters controlling drug tissue 
distribution or excretion (Giacomini et al., 2010; Lee et al., 2017). Such DDIs can seriously affect 
drug safety and efficacy (König et al., 2013), and regulatory authorities therefore require 
assessment of the DDI risk of new drug candidates (EMA, 2013; FDA, 2017). In many cases, 
transporter-mediated DDIs lead to changes in drug plasma PK and can therefore be detected by 
monitoring plasma concentrations of drugs. In some cases, however, inhibition of transporters 
may predominantly affect drug tissue concentrations (Kusuhara & Sugiyama, 2009; Patilea-Vrana 
& Unadkat, 2016). For instance, inhibition of efflux transporters in the canalicular membrane of 
hepatocytes or in the brush border membrane of kidney proximal tubule cells may lead to changes 
in liver and kidney concentrations of drugs. Nuclear imaging methods allow assessment of tissue 
concentrations of radiolabeled drugs and have therefore been proposed as a tool to investigate 
such silent DDIs (Kusuhara, 2013; Langer, 2016; Wulkersdorfer et al., 2014). Consequently, 
several groups have developed radiolabeled probe substrates for measuring the activities of ABC 
and SLC transporters in different organs with PET (e.g. brain, liver and kidney) (Langer, 2016; 
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Marie et al., 2017; Testa et al., 2015). Most of these probes lack selectivity for a single ABC or 
SLC transporter.  
Japanese researchers around Prof. Yuichi Sugiyama developed several PET probe substrates to 
measure the activities of sinusoidal uptake transporters in hepatocytes ((15R)-[11C]TIC-Me, 
[11C]telmisartan, [11C]dehydropravastatin) (Kusuhara, 2013). (15R)-[11C]TIC-Me is a methyl ester 
which is rapidly converted into its free acid (15R)-[11C]TIC in blood. In one study it was shown that 
CLuptake,liver and CLint,bile of (15R)-[11C]TIC-associated radioactivity were reduced in healthy human 
subjects after oral treatment with rifampicin, which was attributed to inhibition of sinusoidal OATPs 
(OATP1B1, OATP1B3) and possibly canalicular MRP2 (Takashima et al., 2012). Similar results 
were obtained with [11C]dehydropravastatin after rifampicin treatment in humans (Kaneko et al., 
2018). Metformin is a widely used oral antidiabetic drug. PET studies with [11C]metformin revealed 
pronounced changes in liver and kidney distribution of [11C]metformin in rodents when uptake 
transporters (mOCT1 and mOCT2) and efflux transporters (mMATE) were pharmacologically 
inhibited with cimetidine and pyrimethamine, respectively (Shingaki et al., 2015; Jensen et al., 
2016). The radiolabeled epidermal growth factor receptor-targeting tyrosine kinase inhibitor (TKI) 
[11C]erlotinib was found to be transported in vitro at low concentrations as used for PET imaging 
by OATP2B1, but not by OATP1B1 and OATP1B3, whereas OATP2B1 transport was saturated 
at pharmacologic erlotinib concentrations. In vivo, liver uptake of [11C]erlotinib was markedly lower 
after pre-treatment of healthy volunteers with a therapeutic erlotinib dose as compared with 
administration of a microdose of [11C]erlotinib, which appeared to be caused by saturation of 
OATP2B1 transport (Bauer et al., 2017b) (Fig. 6). These data suggested that erlotinib may be a 
perpetrator of OATP2B1-mediated DDIs when combined with drugs which are mainly taken up 
into the liver by OATP2B1. Moreover, [11C]erlotinib may be useful as an OATP2B1-specific probe 
substrate for PET studies. 
The SPECT tracer [99mTc]mebrofenin is a substrate of OATP1B1, OATP1B3, MRP2 and MRP3 
(de Graaf et al., 2011; Ghibellini et al., 2008). Pfeifer et al. demonstrated in a SPECT study in 
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healthy volunteers that oral pretreatment with ritonavir decreased CLuptake,liver of [99mTc]mebrofenin 
by 46%, which was attributed to inhibition of OATP1B1 and OATP1B3 (Pfeifer et al., 2013).  
The entry of gadoxetate and BOPTA into hepatocytes is mediated by OATP1B1 and OATP1B3, 
and they are secreted into bile in unchanged form through MRP2. Kato et al. investigated the 
interaction between gadoxetate and 11 clinically used drugs in rats using MRI (Kato et al., 2002). 
They found a significant decrease in contrast enhancement of the liver when rats were pre-treated 
with rifampicin, but concluded that a combination of gadoxetate and rifampicin is unlikely to occur 
in the clinic. One study in healthy volunteers investigated the interaction between gadoxetate and 
the macrolide antibiotic erythromycin, which inhibits OATP1B1 and OATP1B3 in vitro (Seithel et 
al., 2007), and failed to detect a significant effect of erythromycin on liver enhancement (Huppertz 
et al., 2011).  
PET imaging has been useful in evaluating the risk for DDIs at the level of ABC transporters 
expressed at the BBB, which may lead to increased brain distribution of drugs and CNS side 
effects (Eyal et al., 2009b). In a seminal position paper, Kalvass and colleagues argued that 
transporter-mediated DDIs at the BBB are unlikely to occur in clinical practice as most marketed 
drugs do not achieve high enough unbound plasma concentrations to lead to significant efflux 
transporter inhibition at the BBB (Kalvass et al., 2013). Exceptions are the immunosuppressant 
drug cyclosporine A, which was shown to increase brain exposure of [11C]verapamil 1.8-fold when 
administered as an intravenous infusion concurrent with the PET scan (Sasongko et al., 2005). 
The antiarrhythmic agent quinidine was also shown to exert a small P-gp inhibitory effect at the 
human BBB at clinically relevant plasma concentrations (Liu et al., 2015). In contrast to the 
majority of marketed drugs, several non-marketed, experimental P-gp inhibitors which were 
originally developed as MDR reversal agents (e.g. elacridar, tariquidar and valspodar) (Szakács 
et al., 2006) were shown to lead to significant increases in brain distribution of P-gp substrates. 
For instance, up to 4- to 5-fold increases in brain distribution of (R)-[11C]verapamil or [11C]N-
desmethyl-loperamide were observed in healthy volunteers when tariquidar was intravenously 
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infused during the PET scan (Bauer et al., 2015; Kreisl et al., 2015). These studies do not 
represent realistic scenarios for clinically relevant transporter-mediated DDIs at the BBB as they 
employed non-marketed drugs dosed intravenously at rather high doses. Nevertheless, these data 
suggest that efflux transporter inhibition at the human BBB is in principle feasible and may be 
exploited to enhance brain distribution of drugs targeted to the brain.  
4.4 Imaging the impact of transporter gene polymorphisms on transporter function 
Polymorphisms in the genes encoding transport proteins were shown to be associated with 
alterations in transporter activity and expression, leading to inter-individual variability in drug 
disposition and drug response (Ieiri, 2012; König et al., 2006; Maeda & Sugiyama, 2008; Niemi et 
al., 2011). Imaging with radiolabeled transporter substrates is an obvious way to assess the 
functional impact of these genetic variants in different tissues, and a handful of clinical studies 
have so far been published.  
Two studies assessed the impact of a combination of three different ABCB1 SNPs on brain 
distribution of racemic [11C]verapamil (Brunner et al., 2005; Takano et al., 2006). Both studies 
failed to detect differences in [11C]verapamil brain distribution between healthy homozygous 
carriers of the TTT haplotype (c.3435T, c.2677T, and c.1236T) and homozygous carriers 
(controls) of the CGC haplotype (c.3435C, c.2677G, and c.1236C). Interestingly, a study in AD 
patients by van Assema found an association between T dose in the c.C1236T, c.G2677T and 
c.C3435T SNPs and BPND of (R)-[11C]verapamil (van Assema et al., 2012c). Carriers of the variant 
alleles had a higher BPND than non-carriers, which was interpreted by the authors as decreased 
P-gp function at the BBB. The same study found no effect of these ABCB1 SNPs on brain 
distribution of (R)-[11C]verapamil in healthy control subjects, which confirmed the results obtained 
by Brunner and Takano (Brunner et al., 2005; Takano et al., 2006) and suggested that genetic 
variations in the ABCB1 gene might affect P-gp function or expression at the BBB only when P-
gp function is already compromised. The most important SNP in the ABCG2 gene is c.421C>A. 
This non-synonymous SNP has been associated with diminished expression of BCRP in various 
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tissues, such as the liver, placenta and intestine (Kobayashi et al., 2005; Prasad et al., 2013) and 
with changes in plasma PK of BCRP substrate drugs, such as sulfasalazine and rosuvastatin 
(Keskitalo et al., 2009; Yamasaki et al., 2008). Bauer et al. used a newly developed PET protocol 
(Wanek et al., 2012) to measure the impact of this ABCG2 SNP on the function of BCRP at the 
BBB (Bauer et al., 2016). This PET protocol is based on PET scans with the dual P-gp/BCRP 
substrate [11C]tariquidar, in which unlabeled tariquidar is co-administered to inhibit P-gp and 
eliminate the contribution of P-gp to brain distribution of the dual substrate. Bauer reported 1.7-
fold higher [11C]tariquidar VT values in heterozygous SNP carriers (c.421CA) as compared with 
non-carriers (c.421CC), which was consistent with reduced BCRP transport activity at the BBB of 
SNP carriers (Bauer et al., 2016). Interestingly, no difference in [11C]tariquidar brain distribution 
was observed between carriers and non-carriers in PET scans without tariquidar co-
administration, which indicated that the effect of the ABCG2 SNP was masked in presence of 
functional P-gp. Variants in the SLC22A1 gene, which encodes OCT1, were shown to affect OCT1 
function and expression and have been associated with altered response to the oral antidiabetic 
drug metformin compared with carriers of the reference allele, without affecting metformin 
systemic exposure (Zamek-Gliszczynski et al., 2017). This is because the liver is the target organ 
of metformin distribution and pharmacologic activity, but the drug is ultimately eliminated by the 
kidney. Sundelin et al. showed that exposure of [11C]metformin in the liver was significantly lower 
in carriers of p.M420del and p.R61C variants in SLC22A1 after both oral and intravenous 
administration of the PET tracer (Sundelin et al., 2017). This supported the notion that genetic 
SLC22A1 variants may affect metformin response. Two studies found diminished liver 
enhancement with gadoxetate in carriers of SLCO1B1 SNPs without changes in plasma PK of 
gadoxetate, suggesting that genetic transporter variants may be signal confounders in 
gadoxetate-enhanced diagnostic liver MRI (Nassif et al., 2012; Okubo et al., 2013). One study 
examined liver distribution of [99mTc]mebrofenin in healthy volunteers and patients with 
nonalcoholic steatohepatitis and found a diminished CLuptake,liver of [99mTc]mebrofenin in healthy 
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volunteers who were carriers of low/intermediate function SLCO1B1 genetic variants (Ali et al., 
2017). It can be expected that transporter polymorphisms will also affect tissue uptake of other 
clinically used diagnostic radiotracers or contrast agents and should therefore be considered in 
the interpretation of imaging data.  
4.5 Animal to clinical extrapolation 
Species differences have been reported in the substrate recognition and transport efficacy of ABC 
and SLC transporters (Kim et al., 2008; Li et al., 2008; Xia et al., 2006; Yamazaki et al., 2001). 
For instance, it has been shown that antiseizure drugs are good substrates of mouse P-gp 
(mABCB1A), whereas they are only weakly transported by human P-gp (Baltes et al., 2007; Luna-
Tortós et al., 2008). The PET tracer [18F]MPPF (4-(2'-methoxyphenyl)-1-[2'-(N-2"-pyridinyl)-p-
[18F]fluorobenzamido]ethylpiperazine) was shown to be transported by mABCB1A, but not by 
human P-gp (Tournier et al., 2011, 2012). Direct murine orthologues do not exist for some drug 
transporters. For example, in the sinusoidal membrane of human hepatocytes the SLCO 
transporters OATP1B1, OATP1B3 and OATP2B1 are expressed, whereas in mouse hepatocytes 
mOATP1B2, mOATP2B1, mOATP1A1 and mOATP1A4 are expressed (Durmus et al., 2016). 
mOATP1B2 is the mouse orthologue of human OATP1B1 and OATP1B3. mOATP1A1 and 
mOATP1A4 are mouse orthologues of human OATP1A2, which in the human liver is not 
expressed in the sinusoidal hepatocyte membrane but in epithelial cells of the bile duct. Owing to 
these differences, preclinical data on OATP-mediated transport in rodent liver is notoriously 
difficult to extrapolate to humans (Durmus et al., 2016) (Fig. 6). The advent of quantitative targeted 
absolute proteomics has provided a tool to quantify absolute expression levels of transport 
proteins in different organs and tissues (Ohtsuki et al., 2011). These studies, too, revealed 
pronounced species differences in transporter expression. For instance, while BCRP was shown 
to be the most abundant ABC transporter at the human BBB, P-gp (mABCB1A) was found to be 
more abundant at the mouse BBB than mBCRP (Shawahna et al., 2011; Uchida et al., 2011). 
While mMRP4 was detected as the third most abundant ABC transporter at the mouse BBB, it has 
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not yet been detected at the human BBB (Uchida et al., 2011). Such species differences are 
expected to lead to species differences in tissue distribution and excretion of PET/SPECT 
radiotracers and MRI contrast agents which are transporter substrates. Owing to the availability 
of dedicated small-animal PET, SPECT and MRI systems, differences between rodents and 
humans can be directly investigated in a translational approach using the same technology. 
However, several caveats have to be kept in mind. One important issue is the fact that imaging 
studies in rodents are usually performed under anaesthesia (e.g. isoflurane), while this is not the 
case in humans. Second, it is well known that species differences also exist in metabolism 
pathways of xenobiotics (Martignoni et al., 2006). Therefore, species differences in radiotracer 
metabolism may mask species differences in drug transporters. Third, several key physiological 
parameters differ between rodents and humans (e.g. organ blood flow) (Davies & Morris, 1993), 
which may also exert an influence on tissue distribution of radiotracers. Some imaging studies 
have attempted to address these issues specifically. Syvänen et al. assessed differences between 
rats, monkeys and humans in brain distribution of three radiolabeled P-gp substrates 
([11C]verapamil, [11C]GR205171 and [18F]altanserin). These authors found higher brain-to-plasma 
ratios of radioactivity in monkeys or humans as compared with rats, and higher increases in brain 
distribution of these radiotracers following cyclosporine A treatment in rats than in monkeys 
(Syvänen et al., 2009). Similarly, P-gp inhibition with tariquidar at comparable tariquidar plasma 
concentrations produced a higher increase in brain uptake of (R)-[11C]verapamil in rats than in 
humans (Kuntner et al., 2010; Bauer et al., 2012; Wagner et al., 2009) (Fig. 4). In accordance with 
this, in vivo half-maximum inhibitory concentrations for enhancement of brain uptake of (R)-
[11C]verapamil by tariquidar were determined to be lower in rats (873 nM) than in humans (2,248 
nM) (Bauer et al., 2015; Kuntner et al., 2010) (Fig. 4). This stands in contrast with data for 
cyclosporine A, for which increases in brain uptake of [3H]verapamil achieved in rats were found 
to predict increases in brain uptake of [11C]verapamil in humans (Hsiao et al., 2006). Wanek et al. 
systematically assessed possible reasons for species differences in brain distribution of (R)-
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[11C]verapamil and [11C]N-desmethyl-loperamide (Wanek et al., 2015). They concluded that 
species differences in metabolism along with brain uptake of radiolabeled metabolites precluded 
an assessment of species differences in P-gp transport activity at the BBB with these two 
radiotracers. Consequently, for an assessment of species differences in ABC and SLC transporter 
activities, the availability of radiotracers that are not metabolized over the duration of a PET scan 
in all investigated species is mandatory.  
No general recommendations can be made as to which preclinical species better predicts the 
pharmacokinetic disposition of an imaging probe in humans. For instance, with respect to P-
gp/BCRP activity at the BBB, non-human primates have been identified as a more appropriate 
model of the human BBB than rodents (Ito et al., 2011; Uchida et al., 2011). In recent years, efforts 
have been directed toward the development of mouse models humanized for certain ABC or SLC 
transporters or metabolizing enzymes (Choo & Salphati, 2018). These mouse models still suffer 
from certain limitations. In most cases, for instance, the models are only humanized for a single 
transporter gene and compensatory up-/down-regulation of other transporters or enzymes may 
occur. Nevertheless, these animal models may ultimately allow a better translation of transporter 
imaging results from mice to humans. Finally, it should be emphasized that PET and SPECT use 
sub-pharmacological doses (microdoses) of imaging probes, so that toxicity issues are not usually 
of concern in imaging experiments in humans. In many cases, transporter imaging probes are 
derived from known drugs or drug metabolites, and regulatory hurdles preventing rapid translation 
of PET tracers from preclinical species into humans are much smaller than in conventional drug 
development (ICH Expert Working Group, 2009). Consequently, while rodent experiments may be 
very useful in developing and improving methodological aspects and addressing certain 
questions, such as the tissue content of radiolabeled metabolites, small pilot studies in healthy 
human volunteers may be the best way to assess the suitability of a novel transporter imaging 
probe for clinical use. 
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4.6 Pharmacokinetic imaging to study the fate of drugs at the site of action 
The study of drug transporters with imaging modalities most commonly relies on the use of 
prototypical probe substrates. These are ideally designed to be specific to one transporter with 
high transport capacity, in order to generate substantial “contrast” between conditions where 
transporter activity is absent or present (Kannan et al., 2009; Wanek et al., 2015). However, 
quantitative data obtained with one prototypical probe substrate for one transporter might not be 
readily translated to other substrates of this transporter. Indeed, xenobiotics have different 
affinities for transporters, and scaling factors and suitable models have to be considered to 
extrapolate the in vivo impact of transporters on the tissue permeation of drugs of interest (Kalvass 
et al., 2013; Matsuda et al., 2017). Moreover, most drugs are often substrates of multiple 
transporters and considerable overlap between ABC and SLC substrates is commonly observed 
(Gui et al., 2010; Matsson et al., 2009). Substrates of influx transporters may also undergo efflux 
transport at the same interface. In this situation, the overall net flux of the drug results from the 
competition between the influx and efflux component, which is difficult to predict in the real-life 
situation (Chapy et al., 2016; Taskar et al., 2017). 
As an alternative to the use of prototypical probe substrates, direct isotopic labeling of the drug of 
interest may be employed. Theoretically, the study of drug distribution in selected organs and 
exposure to target/vulnerable tissues is feasible. However, careful interpretation of PET data is 
required to avoid any misinterpretation regarding drug exposure to investigated tissues. In most 
situations, radioactivity in tissues cannot be straightforwardly converted into local drug 
concentrations at the sites of action (Pike, 2009). Conventional pharmacokinetic studies 
accurately measure the free ligand in plasma and are able to detect the presence of metabolites 
using analytical chemistry methods. However, PET-based kinetic imaging does not distinguish 
between radioactivity associated with the vascular content, the free, bound, and parent 
compounds, and radiolabeled metabolites in tissues (Pike, 2009).  
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So far, pharmacologic imaging has predominantly focused on the interaction of drugs with their 
respective molecular targets in tissue through receptor occupancy (now named target 
engagement) studies (Willmann et al., 2008). Advances in PET data acquisition and modeling 
have considerably enhanced the applicability of imaging biodistribution studies and paved the way 
for what could be named pharmacokinetic imaging. When drugs are amenable to radiolabeling, it 
is now possible to investigate the interplay of membrane transporters in controlling the clearance 
and tissue distribution of drugs. Using this approach, the impact of SLC and ABC transporters has 
been revealed in a dynamic fashion for glyburide (Tournier et al., 2013), metformin (Jensen et al., 
2016), sulpiride (Takano et al., 2017), metoclopramide (Pottier et al., 2016), ciprofloxacin (Wanek 
et al., 2016) and erlotinib (Bauer et al., 2017b; Traxl et al., 2015), to cite a few examples. This 
emerging approach is increasingly regarded as a means to elucidate the overall impact of 
membrane transporters on drug distribution to tissues in animals and humans (Giacomini et al., 
2010). A step forward in modern pharmacology will be to investigate transporter-mediated drug 
uptake by tissues as a mediator of local drug exposure to tissues, and ultimately to assess or 
predict the contribution of membrane transporters to pharmacodynamics and toxicity. This 
approach is gaining attention for the study of drug delivery to sanctuary tissues, mainly in cancer. 
For instance, the poor CNS permeation of TKIs is now accepted as a determinant of the poor 
response of CNS malignancies, including brain metastasis, to this class of molecularly targeted 
therapy (Holohan et al., 2013; Camidge et al., 2014). PET using radiolabeled analogs of TKIs can 
be regarded as a useful method to compare their CNS penetration in humans (Verheijen et al., 
2017) and non-human primates, a relevant animal model of the human BBB (Ballard et al., 2016; 
Collier et al., 2017a, 2017b). Virtually all members of the clinically important class of TKIs were 
identified as dual P-gp/BCRP substrates, which provides a mechanistic explanation for their low 
brain penetration (Agarwal et al., 2011; Durmus et al., 2015). Recent studies used [11C]erlotinib 
PET imaging to evaluate strategies to improve the brain delivery of erlotinib. P-gp/BCRP-mediated 
efflux of erlotinib at the BBB was inhibited using an intravenous infusion of high-dose elacridar in 
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non-human primates (Tournier et al., 2017). However, P-gp/BCRP inhibition could not be achieved 
using an oral formulation of elacridar in humans, most likely due to the low oral bioavailability of 
this inhibitor (Verheijen et al., 2017).  
Despite its methodological limitations, pharmacokinetic imaging is a potentially powerful approach 
to evaluating transporter-based strategies to improve the local delivery and/or tissue selectivity of 
drugs at their sites of action. Applications may not only be restricted to research in cancer therapy, 
but may also be extended to neurological or infectious diseases for which sanctuary sites are 
suspected to account for poor or incomplete therapeutic response in patients (Rizk ML et al., 
2017). Moreover, radiolabeled drugs may find use in evaluating protective pharmacologic 
strategies to mitigate organ toxicities of certain drugs (e.g. nephrotoxicity) (Manohar & Leung, 
2017; Reichart et al., 2017).  
5 Expert opinion and perspectives 
Imaging methods are increasingly regarded as innovative means to explore drug transporters in 
vivo. Advances in the development of imaging probes dedicated to the study of drug transporter 
function has provided new insights into the role of drug transporters at several blood-tissue 
interfaces. However, imaging techniques still suffer from several technical and methodological 
limitations, which restrict their applicability to transporter studies. Limitations related to the inability 
of nuclear imaging methods to distinguish parent compound from radiolabeled metabolites have 
been discussed in this review article. Therefore, metabolically stable probe substrates are clearly 
preferred for transporter imaging studies. Regulatory authorities request that pharmaceutical 
companies examine the interaction of new drug candidates and their metabolites with ABC and 
SLC transporters to assess the risk for the occurrence of DDIs (EMA, 2013; FDA, 2017). Hence, 
it can be assumed that a wealth of unpublished data are available on new chemical entities which 
never reached the market but which may prove suitable for the development of transporter imaging 
probes. Clearly, the field may benefit considerably from public-private partnerships between 
academic researchers and pharmaceutical companies in order to advance transporter imaging. A 
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major challenge in the imaging of transporters is related to the broadly overlapping substrate 
specificities of most ABC and SLC transporters, so that true transporter selectivity may be difficult 
to achieve in practice. However, the introduction of carefully matched, clinically feasible 
combinations of radiolabeled probe substrates with prototypical transporter inhibitors may prove 
beneficial in revealing the role played by specific ABC and SLC transporters in certain organ 
systems. For instance, lack of selectivity of a radiolabeled probe substrate for a given ABC or SLC 
transporter may be mitigated by combining it with a transporter inhibitor which inhibits only one of 
the ABC and SLC transporters by which the probe substrate is transported. Therefore, the 
screening of currently available, clinically applicable inhibitors with respect to their transporter 
selectivity profiles should be encouraged in order to yield effective substrate-inhibitor pairs for 
transporter imaging. In this framework, imaging of drug transporters may also clearly benefit from 
medicinal chemistry and structure-activity relationship studies aimed at improving the selectivity 
of transporter substrates and inhibitors (Ekins et al., 2012). It should also be noted that probe 
substrates which lack transporter selectivity in one organ may still prove suitable to selectively 
study a certain transporter in another organ. Therefore, available radiotracers should be further 
evaluated in organs and at blood-tissue interfaces which have not yet been the major focus of 
transporter studies (e.g. BRB, placenta and lungs). Another limitation in the development of 
transporter imaging probes is related to difficulties in extrapolating preclinical results to humans. 
In other words, imaging probes which were identified as suitable for transporter imaging in rodents 
may fail to perform in humans. This is a general problem which is also encountered in drug 
development. This risk may be mitigated by the introduction of more refined and better 
standardized preclinical assessment approaches, such as humanized mouse models, or more 
advanced cell culture experiments, such as sandwich-cultured hepatocytes. However, the key 
strength of imaging methods is that owing to their non-invasive or minimally invasive nature and 
the administration of very low, sub-pharmacological doses of the imaging probes, they are highly 
translational. Given the existence of sometimes pronounced species differences in transporters 
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or metabolizing enzymes, and given the current availability of several prototypical transporter 
inhibitors for clinical use, the best way to characterize the clinical suitability of new imaging probes 
may ultimately be the performance of small pilot studies in healthy human volunteers. This 
approach may also be very useful in the assessment of transporter-mediated DDIs of new drug 
candidates in early clinical drug development. However, further studies with radiolabeled probe 
substrates based on marketed model drugs and prototypical inhibitors are needed to refine 
currently available analytical methodology, such as pharmacokinetic modeling approaches, taking 
into account the inherent limitations of imaging approaches, and to highlight the power of this 
approach in drug development. Another limitation of imaging tools is their high costs and the 
requirement for specialized research infrastructure, in particular for PET imaging. This is where 
less cost-intensive imaging approaches which are better suited to a hospital environment come 
into play. The discovery that MRI contrast agents or SPECT tracers interact with ABC and SLC 
transporters was mostly serendipitous, and so far hardly any systematic efforts have been made 
to develop transporter-specific MRI contrast agents or SPECT tracers. Examples with re-purposed 
SPECT tracers such as [99mTc]mebrofenin have illustrated the power of SPECT to study 
transporters in vivo, particularly in view of recent advances in SPECT methodology. Further 
research should be therefore directed toward the development of SPECT tracers as innovative 
transporter imaging probes with a broader clinical applicability. To establish the clinical benefit of 
transporter imaging, further studies in various disease settings with currently available or newly 
developed imaging probes are required.  
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Figure legends 
Fig. 1. Relative performances of clinical imaging modalities for the study of drug transporter 
function in vivo. The diagram includes positron emission tomography (PET, blue), single photon 
emission computed tomography (SPECT, purple) and magnetic resonance imaging (MRI, 
orange). Scales of the individual axes are proposed for illustrative purposes only. Data and 
corresponding references are reported in the main text for sensitivity, quantification, temporal 
resolution, spatial resolution and availability. Size of the imaging probe portfolio has been 
estimated for each modality from the number of different agents described in the present review.  
 
Fig. 2. Chemical structures of selected imaging agents used to study drug transporters, including 
the SPECT tracer [99mTc]mebrofenin (a) and the MRI contrast agent Gd-EOB-DTPA (gadoxetate) 
(b). Chemistry schemes for the synthesis of (R)-[11C]verapamil by N-methylation of N-desmethyl 
verapamil using [11C]methyl triflate (c) and 3-[18F]fluorocholic acid by nucleophilic 18F-fluorination 
of a protected mesylated precursor (d) are reported.  
 
Fig. 3. Kinetic model of the transport of [11C]cholylsarcosine (11C-CSar) from blood to bile. The 
exchange of 11C-CSar between the compartments is described by fitted parameters: K1 (mL 
blood/min/mL liver tissue), k2 (min-1), k3 (min-1), and k5 (min-1). The amount of 11C-CSar in the blood 
compartment at time t is Cin(t) multiplied by Vblood (the fraction of blood in the liver tissue, mL 
blood/mL liver tissue). Cin(t) is the flow-weighted mixed input of 11C-CSar to the liver from the 
hepatic artery and the portal vein, which was calculated from the arterial blood concentrations 
measured by arterial blood sampling. The amount of 11C-CSar in the hepatocyte compartment at 
time t is Chep(t) (concentration of 11C-CSar in hepatocytes, kBq/mL hepatocytes) multiplied by Vhep 
(the fraction of hepatocytes in the liver tissue, mL hepatocytes/mL liver tissue). The amount of 11C-
CSar at time t in the intrahepatic bile ducts is Cbile(t) (concentration of 11C-CSar in intrahepatic bile 
  41
ducts; kBq/mL bile) multiplied by Vbile (the fraction of intrahepatic bile ducts in the liver tissue, mL 
bile ducts/mL liver tissue) (reproduced with permission from (Ørntoft et al., 2017)).  
 
Fig. 4. PET summation images of rat (a) and human (b) brain obtained with the P-gp substrate 
radiotracer (R)-[11C]verapamil at baseline and after administration of increasing doses of the third-
generation P-gp inhibitor tariquidar. Radioactivity concentration is normalized to injected 
radioactivity amount per body weight and expressed as standardized uptake value (SUV). 
Concentration-response curves in rats (c) and humans (d) for enhancement of brain uptake of 
(R)-[11C]verapamil (expressed as volume of distribution, VT). Half-maximum inhibitory 
concentrations (IC50) of tariquidar were lower in rats than in humans. Adapted from Bauer et al., 
2012, 2015 and Kuntner et al., 2010. 
 
Fig. 5. Representative [11C]glyburide PET data obtained in the liver of one non-human primate. 
Pre-treatment with the OATP inhibitor rifampicin resulted in a pronounced decrease in 
[11C]glyburide uptake by the liver (a, b). This resulted is a marked increase in [11C]glyburide plasma 
concentrations (c) and the recovery of parent (unmetabolized) [11C]glyburide in plasma (d). 
Radioactivity concentration is normalized to injected radioactivity amount per body weight and 
expressed as standardized uptake value (SUV). Adapted from Tournier et al., 2013.  
 
Fig. 6. Serial abdominal PET images recorded in mice (a) and humans (b) after intravenous 
injection of a microdose of [11C]erlotinib (scan 1) and after injection of a microdose of [11C]erlotinib 
mixed with a pharmacologic dose of unlabeled erlotinib (10 mg/kg) (mice) or after pre-treatment 
with an oral therapeutic dose of erlotinib (300 mg) (humans) (scan 2). Anatomical structures are 
labeled with arrows (L, liver; GB, gall bladder; C, colon; D, duodenum; BD, bile duct). Radioactivity 
concentration is normalized to injected radioactivity amount per body weight and expressed as 
standardized uptake value (SUV). Concentration-time curves of [11C]erlotinib in the liver of mice 
  42
(c) and humans (d) for scan 1 and scan 2. The effect of unlabeled erlotinib on liver distribution of 
[11C]erlotinib is more pronounced in humans than in mice. Adapted from Bauer et al., 2017 and 
Traxl et al., 2015. 
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